NOV 12, 2015 01:30 PM PST

NGS in clinical research

1 12 1305

  • Senior Global Product Manager, NGS, Qiagen
      Jennifer Fostel has her masters in Molecular and Cell Biology from University of California at Berkeley. She did her graduate research in Dr. Susan Marqusee's lab where she analyzed the key properties of proteins from thermophilic and mesophilic microbial species. She has worked in next-generation sequencing for the last seven years, including management of clinical next generation sequencing projects for the Broad Institute of MIT and Harvard as well as NGS biomarker assay development for Takeda Pharmaceuticals oncology translational medicine. Today at QIAGEN Jennifer is a Senior Global Product Manager, covering a portfolio of universal workflow NGS library preparation products.


    Currently, next-generation sequencing is not only being used for basic discovery research but also in clinical settings for translational biomarker profiling and clinical research studies including inherited diseases and cancer.   Implementing a clinical-grade NGS assay is complex as it requires expertise in technology, medicine, and bioinformatics, and as a result, clinical standards for NGS are still being established by regulatory agencies and disease communities.   In addition to technical expertise, there are other strategic decisions that need to be made prior to implementing an NGS assay in a clinical environment.  These include selecting the most appropriate NGS assay for the clinical purpose, laboratory validation of the assay, and choosing a partner lab if you intend to outsource sequencing. The webinar will provide an introduction to some of these questions in NGS clinical research. 

    In this webinar you will learn
    1.    How NGS data differs from array or qPCR assays
    2.    Strategies for NGS sequencing: WGS, WES and Targeted DNA sequencing 
    3.    Considerations for validating an NGS assay for clinical use

    Show Resources
    Loading Comments...